DIPG Treatment with MK-1775 and Local Radiation – Phase I

MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Protocol Description

This Children’s Oncology Group Phase I trial studies the effects of MK-1775 when given with localized radiation therapy in treating young patients with newly diagnosed diffuse intrinsic pontine gliomas (DIPG), a condition for which there is no standard treatment. The drug may help stop tumor cells by blocking some enzymes needed for their growth. Researchers believe use of MK-1775 in combination with radiation may work better than radiation therapy alone.
Study Level: Phase I

Eligibility Criteria

Subject to certain exclusion criteria, this study is open to males and females, ages 37 months to 21 years with newly diagnosed DIPG.
Males and Females: Ages 37 months to 21 years


Treatment consists of radiation therapy every weekday for 6 weeks for a total of 30 treatments. MK-1775 will be given as a capsule by mouth following radiation therapy according to dosage level protocols for this study. Blood work and other tests, as well as periodic evaluations will be required at specific intervals. After completing the therapy, participants will be followed by study doctors every 2 to 3 months.
Visits: 30 for radiation treatments
Duration: 6 weeks for therapy, plus extended follow-up

Status: Open for Enrollment

Source(s) of Support

Children’s Oncology Group (Study ADVL1217)
National Cancer Institute, Cancer Therapy Evaluation Program

Primary Investigator

Jean Tersak, MD

Contact Information

For more information about the study or enrollment, please contact:
Research Coordinator Angela Connelly, RN, BSN